For Immediate Release
NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES
Jenex Reports Expected Date of Test Results for TherOZap™ at Inactivating the Zika Virus
Toronto, Ontario – (September 14, 2017) The Jenex Corporation (“Jenex”, or the “Company”, NEX: JEN.H), a progressive medical device technology company, would like to report that the Techna Institute at UHN has informed Jenex that the initial data results for TherOZap™ at inactivating the Zika virus are expected to be received during the week of October 2nd with an outside reporting date during the second week of October. Techna Institute has informed Jenex that additional time may be required outside of the first week of October if necessary to provide the data. Jenex expects to report additional information on the various tests being performed with the TherOZap™ as it receives the information from Techna Institute to determine the TherOZap™ ability to inactivate the Zika virus.
Rob Fia, CEO, commented:
“We would like to thank our shareholders for demonstrating patience while awaiting the testing of TherOZap™ with Techna Institute at UHN. Jenex has added additional testing parameters which has caused some of the delays as the Company felt it was prudent to investigate testing the device as broadly as possible. We are as excited as our shareholders to receive the initial tests results and we ask that shareholders continue to be patient as we expect additional information related to testing TherOZap™ throughout the rest of 2017.”
Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs. Clear and healthy skin for all is at the core of Jenex’s philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments. The Company’s breakthrough proprietary technology delivers effective, non-invasive and pain free skin care. The Jenex Corporation trades on the NEX (NEX: JEN.H). For more information visit: www.thejenexcorporation.com or www.therozap.com
About Techna Institute:
Techna is an institute of the University Health Network, in collaboration with the University of Toronto, focused on the accelerated development and exploitation of technology for improved health.Techna is designed to shorten the time interval from technology discovery and development to application for the benefit of patients and the health care system. It also stimulates and facilitates the innovation cycle through a continuum of clinically driven innovation, technology & process development, and translational research. For more information visit: technainstitute.com
About University Health Network:
University Health Network (UHN) is a major landmark in Canada’s healthcare system and a teaching partner of the University of Toronto. UHN consists of Toronto General and Toronto Western Hospitals, the Princess Margaret Cancer Centre, Toronto Rehabilitation Institute and the Michener Institute for Education at UHN. The scope of research and complexity of cases at University Health Network has made it a national and international source for discovery, education and patient care. It has the largest hospital-based research program in Canada, with major research in cardiology, transplantation, neurosciences, oncology, surgical innovation, infectious diseases, genomic medicine and rehabilitation medicine. For more information visit: www.uhn.ca
FORWARD LOOKING STATEMENTS
Certain statements in this news release constitute “forward-looking” statements. These statements relate to future events or the Company’s future performance and include tests involving the Company’s TherOZap™ technology and expected test results for the technology at inactivating the Zika virus as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. In addition to other risks, the Company’s tests involving TherOZap™ may prove to be unsuccessful against the Zika virus and the Company may be unable to complete the consumer product TherOZap™ technology. Further, the Company may not complete the tests on the schedule it expects as described in this news release or attract capital for marketing to ramp up sales or establish recurring revenue in the future to generate cash flow for the Company. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
|For Further information please contact: